Different medical institutions have selected different imported and domestic brand instruments: 38 domestic and 58 imported.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

The global point of care (POC) diagnostics/testing market size is expected to grow at a CAGR of 3.3% over the forecast period 2019-2025 to reach USD 22.8 billion by 2025, driven by the ability of POC tests to render rapid and accurate resu

The US Food and Drug Administration has approved Qiagen's Therascreen PIK3CA RGQ PCR Kit as a companion diagnostic for identifying which advanced breast cancer patients have PIK3CA mutations and are likely to respond to Novartis' alpelisib (

Roche said recently that it has received US Food and Drug Administration 510(k) clearance for its Cobas TV/MG test for the detection of Trichomonas vaginalis (TV) and Mycoplasma genitalium (MG) DNA in symptomatic and asymptomatic patients.

PreludeDx said recently that the State of New York Clinical Laboratory Evaluation Program (CLEP) has approved its DCISionRT test, which assesses recurrence risk and can predict radiation therapy benefit in patients diagnosed with non-invasiv

Turning Point Therapeutics and Almac Diagnostic Services recently announced approval by the US Food and Drug Administration of an investigational device exemption for use of an Almac diagnostic assay to determine whether cancer patients are

German molecular diagnostics firm Curetis said recently that it will receive €6.5 million ($7.3 million) in gross proceeds under two financing facilities.

NeoGenomics said after the close of the market recently that it has priced its previously announced underwritten public offering of 7 million shares of its common stock at a public offering price of $21.25 per share.

Qiagen reported after the close of the market recently that its first quarter revenues grew nearly 2 percent year over year as the firm fell short of analysts topline estimates but beat expectations on the bottom line. For the three months

PrediLife said recently that it has signed on the Institut Curie to perform the genetic analysis portion of its MammoRisk breast cancer risk assay.

On May 20, 2019, Thermo Fisher Scientific announced that it is investing more than $50 million into its global bioproduction capabilities. The expansion will provide additional capacity for manufacturing single-use bioprocess container (BPC)